Officials from Strongbridge Biopharma plc plan to make their case to the FDA about the potential for an accelerated approval pathway for Recorlev (levoketoconazole) to treat endogenous Cushing's syndrome after the open-label, single-arm SONICS study achieved statistical significance on the pre-specified primary endpoint.